LENZ Projected Dividend Yield
Lenz Therapeutics Inc New ( NASDAQ : LENZ )LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. Co. is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the U.S.. 21 YEAR PERFORMANCE RESULTS |
LENZ Dividend History Detail LENZ Dividend News LENZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |